Bio-Techne Corporation and Veracyte, Inc.: SG&A Spending Patterns Compared

SG&A Spending Trends in the Biotech Sector

In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. Over the past decade, Bio-Techne Corporation and Veracyte, Inc. have showcased distinct patterns in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Bio-Techne's SG&A expenses surged by over 550%, reflecting its aggressive growth strategy. In contrast, Veracyte's expenses increased by approximately 350%, indicating a more measured expansion approach.

Bio-Techne's spending peaked in 2024, with a notable 6% increase from the previous year, while Veracyte's data for 2024 remains unavailable, hinting at potential strategic shifts. These trends highlight the varying strategies within the biotech industry, where companies balance innovation with financial prudence. As the sector evolves, monitoring these financial indicators will be key to understanding future market dynamics.